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Viscum album preparations are aqueous mistletoe plant extracts used in complementary and alternative medicine as
immunomodulators in cancer therapy. However, evidence of immunological eﬃcacy of mistletoe extracts (MEs) used in clinical
trials is often lacking. Mechanisms involved in anti-tumor properties of ME and mistletoe lectins (MLs) modify both innate and
adaptive immune systems, according to animal model experiments. In the background of these eﬀects, a selective binding of
ML on CD75 ganglioside receptors of interleukin 12 (IL-12)-producing macrophages or dendritic cells can play an important
role. Immunological eﬀects of ME correlate with their lectin activity, showing a bell-shaped dose-response curve of eﬃcacy.
Therefore, a correct determination of MLs for the standardization of commercial ME is essential. However, plant MLs exhibit
heterogeneity, which most likely results from post-translational processing. In addition, amino acid analysis of ML has revealed
numerous conservative substitutions along their amino acid sequence. Consequently, ML research needs new perspectives, and the
advantages and disadvantages of puriﬁed and biologically better deﬁned ML preparations are also discussed in this article.
1.Introduction
Viscum album (VA) is a parasitic plant that grows on various
trees. It is commonly known as European mistletoe. VA
preparations are aqueous extracts used as a complemen-
tary medicine in cancer therapy. Various clinical studies
reveal that mistletoe extract (ME) preparations can improve
the quality of life in diﬀerent cancer patients. The most
important biologically active components of ME prepara-
tions are mistletoe lectins (MLs). Other constituents, such
as viscotoxins, Kuttan peptide, polysaccharides, alkaloids,
viscin and vesicles, have also been investigated; but their
exact in vivo role in biological eﬀects of whole ME are still
unclear. Treatment with lectin-containing ME preparations
or puriﬁed ML is associated with tumor regression in several
in vivo experimental models. Mechanisms by which ME
aﬀect cancer cells have been described for various cellular
activities, namely apoptosis [1–5], cell cycle [6, 7], protein
synthesis [8], angiogenesis [9] and immunomodulation
[9–13]. Experiments in animal models suggest that ME-
and ML-mediated inhibition of tumor growth is associated
with their immunomodulatory eﬃcacy. The mechanisms
involved in anti-tumor properties include an enhancement
of interleukin 12 (IL-12) secretion and natural killer (NK)
cell function, which point to an improved balance of the
innate immune system [14]. Case reports and preliminary
clinical observations support these experimental results [15,
16]. Consequently, this review summarizes diﬃculties in the
immunologically eﬀective and reproducible application of
ML and standardized ME in clinical trials. Two essential
problems will be discussed here: (i) the lack of immuno-
logical concepts and evidence in clinical trials carried out
with various ME and (ii) diﬃculties and perspectives with
a standardized and reproducible application of ML and ME.
2. Difﬁculties of the Evidence-Based Judgment
of Immunotherapy by MEs and MLs
2.1. Successful Immunotherapy against Cancer Requires New
Clinical Concepts. In spite of substantial experimental data,













Figure 1: Schematic illustration of the necessity of relationships
between cancer research and immunological and clinical concepts
for a successful immune therapy.
is often insuﬃciently understood, and the correct judgment
of the rather complex immune system in tumor defense is
often controversial. Figure 1 tries to give a schematic illus-
tration about this problem. Clearly, not all immune mech-
anisms are impaired during tumor disease, but the decrease
of several functions of innate immune system supports the
hypothesis that they may contribute to the tumor’s escape
from immune destruction. However, the usual clinical and
laboratory investigations of tumor patients are often unable
to detect any signs of an immune deﬁciency because the
most highly developed speciﬁc immune functions of patients
during tumor progression can remain within normal range.
Despite this discrepancy, experimental research has regularly
found growing evidence that depression of numerous innate
immune functions correlates with progression of cancer.
For example, when the interaction between speciﬁc immune
responses and non-speciﬁc inﬂammatory reactions and their
relation with prognosis of cancer patients were analyzed,
results revealed that although there was a signiﬁcant speciﬁc
anti-tumor response as reﬂected by T cells, their eﬀects on
p a t i e n ts u r v i v a la n dl o c a lr e c u r r e n c ew e r el e s si m p o r t a n t
when compared with eﬀects of non-speciﬁc inﬂammatory
responses [17]. In addition, defects in the major histocom-
patibility complex class I antigen have been described in
tumors of diﬀerent histopathology, which can hinder the
eﬀectiveness of T lymphocytes [18].
Numerous experiments have attempted to ﬁnd reasons
for the decreased activity of the innate immune system in
tumor patients, and there is agreement that soluble factors
produced or induced by malignant cells play an important
role in this depression [19]. In addition, myeloid-derived
suppressor cells have also been found to be responsible
for this phenomenon [20]. In spite of the fact that basic
functions of the innate immune system are depressed in
tumor patients, its investigation is not in current clinical
praxis, causing a continuous lack of fresh clinical experi-
ence and emerging concepts. This lack of understanding
in evidence-based medicine has hindered development of
various kinds of non-speciﬁc immunotherapy modalities






























Figure 2: Balance of innate immune system (schematic and simple
represented by arrows with directed lines) and presumable eﬀect
of ML given with ME (represented by arrow with broken lines).
The signal “+” means a stimulatory eﬀect and “−” indicates
an inhibitory eﬀect. As shown, ML stimulates pro-inﬂammatory
cytokines and IL-12-producing macrophages and dendritic cells
[11, 12, 23]. This ﬁgure represents a modiﬁed version of an
illustration published by Murray [24]. ADCC: antibody-dependent
cell-mediated cytotoxicity.
nature of the tumor microenvironment would also be
helpful, although not practical, to better understand these
unspeciﬁc immunotherapeutic interventions.
We must not forget that inﬂammation can exhibit
controversial eﬀects. It may eradicate tumor cells but, when
chronic, may also promote tumor growth. As shown in
Figure 2, M1 macrophages and DC1 dentritic cells generate
IL-12, pro-inﬂammatory cytokines and activate cytotoxic
eﬀector cells, such as NK and NKT cells, which are potent
inhibitors of tumor growth. However, they are defective in
tumor patients. Available information suggests that tumor-
associated macrophages belong to a prototypic M2 popula-
tion [21]. M2 generates IL-4 and IL-10, which facilitate the
generation of T helper 2 (Th2) cells and inhibit Th1 cells
[22]. M2 macrophages aﬀect inﬂammation and promote cell
proliferation by producing growth factors and products of
the arginase pathway as well as promoting angiogenesis and
tissue repair [21].
Tumor patients can have up to 40% more M2 peripheral
monocytes than healthy individuals, who have only 10% M2
monocytes [22]. NKT cells can also have a similar opposing
eﬀect. In cancer, NKT-1 cells are protective, producing
interferon-γ (IFN-γ) to activate NK and DC1 dendritic
cells that produce IL-12. NKT-2 cells primarily inhibit
tumor immunity [25]. These ﬁndings indicate an impaired
balance of the innate immune system in cancer patients.
Consequently, learning to manipulate this balance along the
regulatory axis may be critical to devise successful immune
therapies against cancer.
2.2.TreatmentwithME,asOneoftheMostWidelyUsedAlter-
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Europe, Is Often Not Related to Clear Clinical Immunological
Concepts. Inthelastdecade,clinicalstudyofcomplementary
immune therapy using various plant extracts has progressed
slowly, and the lack of clear immunological concepts often
contributes to this negligence. Figure 1 shows a simpliﬁed
illustration of the relationships between cancer research,
immunological concepts and clinical concepts. Clinicians
often have a feeling that too much is demanded of them. In
the literature of complementary medicine concerning tumor
immunology, there are often speculative pro and contra
arguments. Consequently, it is also not surprising that in
a great number of clinical trials the doses of ME are not
reported; such reports would have enabled a more exact
andreproducible chemicalandimmunological deﬁnition for
using this therapy. Moreover, in spite of emphasis on the
generally accepted opinion that both cytotoxic/apoptosis-
inducing and immunomodulatory eﬀects are important in
the clinical beneﬁt of ME, the immunological results are
lacking in most clinical reports published in the last 20 years.
The latter would have been able to strongly support the
beneﬁcial immunological eﬀectiveness of ME preparations.
This deﬁciency is therefore surprising, because many years
ago a bell-shaped dose-response relationship of ME-induced
immunological eﬀect was established [9–13]. This indicated
that optimal doses are necessary for clinical trials.
3.Clinicaland Immunological Attemptsfor
Monitoringthe ME-/ML-Induced
Improvement of Immune Balance in
Tumor Patients
3.1. Why Is the Investigation of NK Cells Emphasized? As
mentioned above, tumor immunity seems to be restricted to
the M1/D1/NKT-1 pathway of innate immunity, and there-
fore these natural immune mechanisms must be taken into
consideration for successful immunotherapy against cancer
[26]. Activation of this pathway by ML enhances cytotoxic
functions of NK, γδT and NKT cells, which also produce
IFN-γ, and further stimulate M1/D1 cells and inhibit M2/D2
cells (Figure 2). Consequently, the immunological research
of ME and ML focused on the NK system, which seems to be
available for monitoring the M1/D1/NKT-1 pathway of the
innate immune system [11–13].
In previous studies, investigations of NK cells allowed
active dose-dependent results with ML and standardized
ME. In addition, NK cells were also stimulated by ML-I in
vitro, which was, in an additive manner, enhanced by its
combination with IL-2 and IL-12 [11, 12]. In vivo,M L -
I stimulates the activity and peripheral levels of NK cells
showing a bell-shaped curve of eﬃcacy. Studies on animal
models show that application of 0.5–3ng/kgML-I twice a
week is eﬀective to sustain elevation in the number and
activity of peripheral blood NK cells. If lectin injections
were given more frequently (daily), the NK system was not
stimulated, indicating that frequent application may lead
to a situation similar to that regularly observed in chronic
inﬂammation with dominance of the M2/D2/NKT pathway
[11, 12]. Moreover, in healthy persons there is often a high
intrinsic ﬂuctuation in NK activity and frequency. Blind
crossoverstudieshaverevealedanoptimallectindoseof ∼0.5
and1ng/kgifgiventwiceweek[27].Theseresultssuggestthe
potential use of ML and standardized ME as modulators that
can manipulate the balance of the innate immune system in
a clinically more successful direction.
However, most clinical trials using ME do not take
into consideration results of immunological research. Non-
optimal and higher doses of ML and ME do not induce
any signiﬁcant responses in the innate immune system. It
must not be forgotten that cytotoxic eﬀects of ME can down-
regulate their immunological eﬀects if they are not given in
optimal dose [11]. Consequently, the lack of immunological
evidence in many clinical trials with ME makes an objective
judgment of its immunomodulatory potential diﬃcult.
3.2. New Perspectives for Immunotherapy with ML and
Standardized ME. It is well known that novel immunother-
apeutic approaches such as DNA vaccines, dendritic cell
preparations, heat shock protein-based vaccines and gene
transfer technology demonstrated exciting results in animal
experiments, although their evaluation in clinical trials
showed no exceptional tumor protection in a signiﬁcant
number of patients [28]. Consequently, growing evidence
suggests that the eﬀectiveness of tumor-speciﬁc adaptive
immune responses induced by various vaccinating agents
can be enhanced by parallel activation of the appropriate
component of the innate immune system [28].
TheconceptofcancerimmunotherapywithMLprovides
fresh perspectives as it may avoid many of the drawbacks
of conventional therapies, such as chemotherapy, irradiation
and surgery. Targeting the innate immune system in cancer
is of growing importance [28]. Conventional therapy modal-
ities alone do not improve the impaired immune balance
of tumor patients. For example, if the impaired immune
balance of tumor patients before and after chemotherapy is
compared, independent of clinical responses, no diﬀerences
are observed [29].
4. Pharmacochemical Difﬁculties in
StandardizationandReproducible
Application of ME and ML Preparations
4.1. Which Components of ME Are Important in Their
Immunological Standardization? As already mentioned, not
only lectins but also other components such as viscotox-
ins [30], Kuttan peptide [31], polysaccharides [32]a n d
vesicles [33] have been suggested by several authors for
participating in the immunomodulatory eﬃcacy of ME.
However, up to now, these mistletoe components have only
been tested in vitro; only MLs have been veriﬁed in vivo
as substances responsible for the immunological eﬀects of
ME [10, 12, 13, 27]. In a previous study, all types of ML
were completely removed from a commercially available
ME preparation by chromatographic procedures without
causing any other further alteration in the composition of
the extract. The removal of ML from the immunologically
eﬀective ME resulted in immunosuppressive responses in4 Evidence-Based Complementary and Alternative Medicine
healthy volunteers injected with the lectin-free preparation
[10]. This residual immunotoxicity of lectin-free extracts
mayberelatedtoviscotoxins,whichcancytolyticallydamage
cell membranes [34]; other components, such as viscin [35]
may also be involved. Consequently, for the immunological
standardization of MEs, the determination of active MLs is
essential.
4.2. Diﬃculties with Lectin Standardization of ME and ML
Preparations. For the immunological research of ML and
ME, a standardization procedure, namely the enzyme-linked
lectin assay (ELLA), was modiﬁed [10]a n do p t i m i z e d[ 36]
so that the binding capacity of MLs from plants and extracts
to asialofetuin is measured. Since the method is based on
binding lectin to an immobilized oligosaccharide ligand, the
results of the ELLA assay showed a correlation with the
lectin-induced immunological responses observed in in vivo
experiments [10, 12, 13, 27].
As already mentioned, in the standardization of com-
m e r c i a lM E ,t h ec o r r e c td e t e r m i n a t i o no fM L sp l a y sa n
important role. However, plant MLs exhibit a heterogeneity
thatmostlikelyresultsfromthepost-translationalprocessing
of ML-I to the isoforms ML-II and ML-III [37]. Only a
small diﬀerence was found in their primary structures. The
antigenic analysis of B-subunit in ML-I and ML-III showed
one epitope 25RDDDFRDGNQ34 in ML-I that is absent in
the B chain of ML-III, and this diﬀerence can be related
to some gene polymorphism [38]. ME preparations vary
with regard to the content of ML-isoforms, which also may
dependonthemethodofisolationoronvariousdegradation
eﬀects. The chemical deﬁnition of ML-II and ML-III is based
on lower molecular weights, small diﬀerences in primary
structures and observations that N-acetyl-d-galactosamine
(GalNAc) exhibits a more marked inhibition on ML-II-
or ML-III-induced hemagglutination or cytostatic activity
than the galactose-speciﬁc ML-I. In a previous study, MLs
were carefully isolated from fresh plants and commercial
MEs by ultraﬁltration and aﬃnity chromatography. The
direct binding capacity of ML to lactose and GalNAc was
comparedinthesamesystem.Surprisingly,nodirectbinding
to immobilized GalNAc was detected. Only immobilized
lactose was able to bind ML from the specially prepared
extract. These unexpected ﬁndings could be interesting for
further research, which may require new perspectives to ﬁnd
the appropriate binding sites and ligands.
The complete amino acid sequences of the A- and B-
chains of ML-I have been determined [39, 40]. The A-chain
contains 254 amino acid residues, and using matrix-assisted
laser desorption ionization mass spectrometry (MALDI-
MS), the existence of a potential N-glycosylation site was
conﬁrmed [39]. The B-chain is composed of 264 amino
acid residues, and three potential N-glycosylation sites were
conﬁrmed by MALDI-MS analysis [40]. In addition, the
B-chain consists of six subdomains, but only two of them
(1α and 3γ) have sugar-binding receptors, namely the key
residues in 1α receptor, Asp22,G l n 35,T r p 37,A s p 46 and
Gln47, and in 3γ receptor, Asp234,I l e 246,T y r 248,A s n 255 and
Table 1: Advantages and disadvantages of ME and puriﬁed (or
synthetic) ML preparations for clinical use.
Plant ME Puriﬁed or fragmented
biologically active ML
Advantages
Easy to produce Chemically well deﬁned
Inexpensive Biological eﬀect is
reproducible
Now available in pharmacy Dosage calculation is exact
More clinical experiences Less possible side eﬀect
Easy to adapt to CAM
therapy
Disadvantages
Mixture of diﬀerent Expensive to produce
unknown molecules with
diﬀerent biological activity
Biological eﬀect is less Not available in pharmacy
reproducible
Dosage calculation is diﬃcult Lack of clinical experiences
More possible side eﬀects
Gln256. Therefore, the B-chain is the lectin part of the whole
molecule [40].
Manyyearsagoitwasestablishedby2Dgelelectrophore-
sis that there are at least 40 isolectins of ML [41]. For
chemical standardization of the ME preparations applied
clinically, the exact determination of isolectin patterns is
diﬃcult. Amino acid analysis revealed 17 conservative sub-
stitutions along the amino acid sequence of the A-chain [39].
Analyzed sequence data of B-chain also show 12 conservative
substitutions, most of them located in the C-terminal
region of the protein [40]. Because of the heterogeneity of
ML isoforms, an exact immunological standardization of
commercial ME is not easy.
4.3. Using Plant Extract versus Puriﬁed VAA Fragment. Previ-
ous studies with ME revealed that the immunomodulatory
eﬀects and sugar-binding activity of an extract have a
close relationship [11]. Therefore, it would be advisable to
employ a standard procedure for exact and reproducible
determination of the sugar-binding potency of ML and
ME preparations using immobilized ligands with higher
aﬃnity for ML than asialofetuin. Recently, a highly speciﬁc
receptor, the CD75 gangliosides, was described [42, 43],
which is found on numerous eﬀector cells of the innate
immune system [44]. The existence of CD75 receptors may
explain the selective binding capacity of neutrophils and
monocytes to ML [23]. Consequently, ML or their sugar-
binding fragments may be important candidates for an
immunotherapy with a clearly deﬁned targeting strategy.
As shown in Table 1, these puriﬁed ML preparations show
several advantages compared with plant extracts, since the
translation of ME-indeed in vitro and preclinical results
into clinical response continues to pose a problem [45, 46].
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medicine (CAM) are often satisﬁed with ME treatment
because of good subjective results aﬀecting their general
status and fatigue [47]. Commercially available MEs are
mostly given subcutaneously with various frequencies as a
complementary therapy along with traditional cancer treat-
ment. However, an exact summary of the results obtained
with ME in human cancer therapy is not possible because
the application of ME is rather heterogeneous and in many
cases not reproducible. In addition, without appropriate
standardization, ME and ML may induce immunological
side eﬀects, as it was found after high lectin doses in
several cellular immune parameters were tested [10, 12].
As mentioned in Table 1, MEs in high and non-optimal
d o s e sc a ni n d u c em o r es i d ee ﬀects because apart from
the toxic eﬀect of overdosed ML, other toxic substances
(such as viscotoxins and viscin) can also be involved. Using
standardized lectin preparations and fragments may act as
a bridge between the pharmaceutical industry and CAM.
Table 1 summarizes the advantages and disadvantages of
plant extracts and puriﬁed VAA preparations.
5. Conclusions andFuturePerspectives
(1) Successful immunotherapeutic interventions by ML
and ME must be associated with a lectin-induced
improved balance of innate immunity in the tumor
microenvironment. An immunologically optimized
and standardized application of ML and ME may
be helpful in enhancing the quality of life and
prolonging tumor-free survival.
(2) Further pharmacochemical research is necessary to
introduce appropriate standardization procedures
that allow better reproducibility for mistletoe prepa-
rations.
(3) MLs and their fragments may be important candi-
dates for immunotherapy with targeting strategy.
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